Multikine reduced the risk of death by 66% compared to standard of care in the target population of patients with low and zero PD-L1, while Keytruda reduced the risk of recurrence and progression (EFS ...
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...
About head and neck cancer Head and neck cancer describes a number of different tumors that develop in or around the throat, larynx, nose, sinuses and mouth. It is estimated there were more than ...
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain ...
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
On Tuesday, Merck & Co Inc (NYSE:MRK) announced that the Phase 3 KEYNOTE-689 trial of Keytruda (pembrolizumab), as a perioperative treatment for patients newly diagnosed with stage III or IVA, ...
Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS ≥1) The ...
PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...
The Food and Drug Administration today approved Kenilworth, N.J.-based Merck’s best-selling cancer drug Keytruda for additional indications. The drug, currently used for the treatment of melanoma and ...
KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...
“We are excited to see this strong survival benefit for head and neck cancer patients with such cold tumors. Combining these two complementary immunotherapies has led to a 7-fold increase in response ...
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients Provided by ...
Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback